<DOC>
	<DOCNO>NCT01026597</DOCNO>
	<brief_summary>This study test safety tolerability ( body reacts drug ) REGN727 compare placebo ( inactive substance contains medicine ) healthy subject . The study drug placebo administer intravenous ( I.V ) infusion one clinic visit . There 14 clinic visit , include 4 overnight stay . Subjects monitor study staff side effect body 's response study drug . Vital sign ( blood pressure , temperature , breathe heart rate ) check , blood urine sample collect visit .</brief_summary>
	<brief_title>Ascending Dose Study Safety Tolerability REGN727 ( SAR236553 ) Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Male female 18 65 year age . Weight &gt; 50 kg &lt; 95 kg inclusive For woman childbearing potential , negative serum pregnancy test screen visit negative urine pregnancy test day 1 . For men woman childbearing potential , willingness utilize adequate contraception become pregnant ( partner [ ] become pregnant full duration study . Willing , commit , able return clinic visit complete studyrelated procedure . Able read , understand willing sign inform consent form . Initiation new exercise routine major change previous exercise routine within 4 week prior screen visit . Pregnant breastfeed woman . Significant concomitant illness history significant illness cardiac , renal , neurological , endocrinological , metabolic lymphatic disease , illness condition would adversely affect subject 's participation study . Hospitalization reason within 60 day screen . Known history Human Immunodeficiency Virus ( HIV ) antibody ; and/or positive Hepatitis B surface antigen , and/or positive Hepatitis C antibody screen visit . Previous exposure therapeutic investigational biological agent . History alcohol substance abuse within previous 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>